Halozyme Therapeutics | HALO - Ebit

Precio De Mercado
65.40
Cambio Diario
1.80 2.83%
Mensual
-4.02%
Anual
7.83%
Q2 Expectativa
62.55




Ebit Cambio Fecha
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.96B 464M 2025-12
Baxter International USD -214.2M 415.4M 2025-12
Cara Therapeutics USD -5.94M 3.55M 2025-09
Cytokinetics USD -178.37M 11.61M 2025-12
DBV Technologies USD -34.28M 6.83M 2025-09
Eli Lilly USD 8.99B 1.57B 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Intrexon USD -26.3M 2.91M 2024-06
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
MannKind USD -69.24M 28.19M 2025-12
Minerva Neurosciences USD -4.37M 1.71M 2024-09
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Pfizer USD 4.65B 71M 2025-12
Rigel Pharmaceuticals USD 447K 1.52M 2024-06
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -10.28M 721K 2024-12